Hicham I. Cheikh Hassan, Karumathil M. Murali, Jenny H. C. Chen, Judy Mullan
{"title":"Back-up arteriovenous fistula in peritoneal dialysis patients: a retrospective cohort study of long-term meaningful outcomes","authors":"Hicham I. Cheikh Hassan, Karumathil M. Murali, Jenny H. C. Chen, Judy Mullan","doi":"10.1111/imj.70493","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Back-up arteriovenous fistula (bAVF) is used in peritoneal dialysis (PD) to avoid haemodialysis transfer via a central venous catheter (CVC). However, no previous study examined mortality or complications associated with bAVF creation.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>Comparing mortality, haemodialysis transfer overall or with a CVC and vascular access complications (bAVF or CVC) between patients with a bVF and those with no bAVF.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective cohort study of adult PD patients within an Australian Local Health District (2017–2023). Cox regression models were used for hazard ratios (HR) and 95% confidence intervals (95% CI).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 115 patents followed up (median of 1.9 years (interquartile range 0.9, 3.5)), 50 (44%) had a bAVF of which 31 (62%) matured. The bAVF group had 56 procedures (1.1/patient), including 32 assisted interventions (0.6/patient). There was no associated difference in mortality between bAVF and no bAVF group (HR 0.8, 95% CI 0.4–1.6, <i>P</i> = 0.6) or haemodialysis transfer (HR 1.0, 95% CI 0.5–2.0, <i>P</i> = 0.9). A bAVF was associated with a lower haemodialysis transfer risk with a CVC (HR 0.4, 95% CI 0.1–0.9, <i>P</i> = 0.04). Complications between the bAVF and no bAVF group were similar (28% vs 14%, <i>P</i> = 0.06).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>bAVF were associated with lower risk of haemodialysis transfer to haemodialysis with a CVC, compared to those with no bAVF. However, there was no difference in mortality, risk of transferring to haemodialysis or complications.</p>\n </section>\n </div>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"56 9","pages":"1528-1535"},"PeriodicalIF":1.8000,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.70493","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.70493","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Back-up arteriovenous fistula (bAVF) is used in peritoneal dialysis (PD) to avoid haemodialysis transfer via a central venous catheter (CVC). However, no previous study examined mortality or complications associated with bAVF creation.
Aims
Comparing mortality, haemodialysis transfer overall or with a CVC and vascular access complications (bAVF or CVC) between patients with a bVF and those with no bAVF.
Methods
A retrospective cohort study of adult PD patients within an Australian Local Health District (2017–2023). Cox regression models were used for hazard ratios (HR) and 95% confidence intervals (95% CI).
Results
Of 115 patents followed up (median of 1.9 years (interquartile range 0.9, 3.5)), 50 (44%) had a bAVF of which 31 (62%) matured. The bAVF group had 56 procedures (1.1/patient), including 32 assisted interventions (0.6/patient). There was no associated difference in mortality between bAVF and no bAVF group (HR 0.8, 95% CI 0.4–1.6, P = 0.6) or haemodialysis transfer (HR 1.0, 95% CI 0.5–2.0, P = 0.9). A bAVF was associated with a lower haemodialysis transfer risk with a CVC (HR 0.4, 95% CI 0.1–0.9, P = 0.04). Complications between the bAVF and no bAVF group were similar (28% vs 14%, P = 0.06).
Conclusion
bAVF were associated with lower risk of haemodialysis transfer to haemodialysis with a CVC, compared to those with no bAVF. However, there was no difference in mortality, risk of transferring to haemodialysis or complications.
背景:备用动静脉瘘(bAVF)用于腹膜透析(PD),以避免血液透析通过中心静脉导管(CVC)转移。然而,之前没有研究检查与bAVF产生相关的死亡率或并发症。目的:比较bVF患者和无bVF患者的死亡率、整体血液透析转移或伴有CVC和血管通路并发症(bAVF或CVC)。方法:对澳大利亚当地卫生区(2017-2023)的成年PD患者进行回顾性队列研究。风险比(HR)和95%置信区间(95% CI)采用Cox回归模型。结果:115例患者(中位随访1.9年(四分位数间距0.9 ~ 3.5))中,50例(44%)患者发生了bAVF,其中31例(62%)患者已成熟。bAVF组有56例手术(1.1例/例),包括32例辅助干预(0.6例/例)。bAVF组和无bAVF组的死亡率无相关差异(HR 0.8, 95% CI 0.4-1.6, P = 0.6)或血液透析转移(HR 1.0, 95% CI 0.5-2.0, P = 0.9)。bAVF与CVC患者血液透析转移风险降低相关(HR 0.4, 95% CI 0.1-0.9, P = 0.04)。bAVF组和未bAVF组的并发症相似(28% vs 14%, P = 0.06)。结论:与没有bAVF的患者相比,bAVF与血液透析转移到血液透析合并CVC的风险较低相关。然而,在死亡率、转入血液透析的风险或并发症方面没有差异。
期刊介绍:
The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.